What options may exist if GLP-1 coverage through Medicare ends during treatment?

If Medicare stops covering your GLP-1, options include appealing the denial, seeking patient assistance, or discussing alternatives like compounded medications with a doctor.

Why Medicare May End GLP-1 Coverage

Medicare Part D plans provide prescription drug coverage, but they operate under specific federal rules. One key rule, established by law, excludes coverage for drugs used for anorexia, weight loss, or weight gain. This means that while a GLP-1 agonist might be covered for an FDA-approved use like type 2 diabetes, it is generally not covered for chronic weight management alone under a standard Part D plan.

Coverage can end if the plan determines the medication is being used primarily for weight loss rather than for its approved indication of diabetes management. This can be triggered by a plan formulary review, a prior authorization request, or a change in your documented health status.

Furthermore, all Medicare Part D plans have a formulary, which is a list of covered drugs. This formulary can change from year to year. A medication that was covered one year may be moved to a higher-cost tier or removed entirely the next, forcing patients to either pay more or switch medications.

Patients may also experience a sudden increase in cost if they enter the Part D coverage gap, often called the 'donut hole.' In this phase, you pay a higher percentage of your medication costs until you reach a certain out-of-pocket threshold, which can feel like a loss of coverage.

How to Appeal a Coverage Denial

If your Medicare plan denies coverage, you have the right to a formal appeal. The first step is to file a 'Redetermination' request directly with your insurance plan. This is a formal review of the denial. Your prescribing physician's involvement is critical at this stage.

Your physician should submit a letter of medical necessity explaining why the specific GLP-1 medication is essential for your health. This letter should include details of your diagnosis, your treatment history, how you have benefited from the medication, and why alternative covered drugs are not appropriate for you.

Gather all supporting documentation. This includes relevant lab results (like A1c levels), chart notes documenting clinical improvements (e.g., weight reduction, improved blood pressure), and a history of other medications you have tried that were ineffective or caused intolerable side effects.

If the plan upholds its denial, you can proceed through four more levels of appeal, including a review by an Independent Review Entity (IRE). Do not be discouraged by an initial denial, as persistence and strong medical documentation can sometimes lead to a successful appeal.

Manufacturer and Pharmacy Savings Programs

Drug manufacturers often run Patient Assistance Programs (PAPs) to help patients afford their medications. Novo Nordisk, the maker of Ozempic and Wegovy, has the NovoCare program, and Eli Lilly, the maker of Mounjaro and Zepbound, has the LillyCares Foundation.

However, a significant limitation is that many of these programs specifically exclude patients enrolled in government-funded healthcare like Medicare. You must carefully read the eligibility requirements for each program, as some may offer assistance to Part D beneficiaries who meet certain income criteria.

Even if you are ineligible for a PAP, you can still use pharmacy discount cards like GoodRx or SingleCare to lower the cash price of the medication. These cards are free to use and can provide substantial savings, but the final price is still often high for GLP-1s, potentially costing over $1,000 per month.

Note that pharmacy discount coupons cannot be combined with your Medicare Part D insurance. You must choose to pay either your insurance copay or the discounted cash price. The amount paid using a discount coupon does not count toward your annual Medicare deductible or out-of-pocket maximum.

Physician-Supervised Compounded Medications

When brand-name GLP-1s like Wegovy and Mounjaro are listed on the FDA's official drug shortage list, federal law allows licensed pharmacies to compound, or create, medications with the same active pharmaceutical ingredient (semaglutide or tirzepatide) for individual patients with a valid prescription.

It is critical to understand that these compounded medications are not FDA-approved. They have not undergone the same rigorous testing for safety, efficacy, and quality as the brand-name products. Patients should only consider this option under the guidance of a trusted physician.

This option involves a physician evaluating your health needs and, if appropriate, writing a prescription for a compounded medication. This prescription is then sent to a licensed U.S. pharmacy that specializes in sterile compounding. This ensures a baseline of regulatory oversight for the pharmacy's operations.

Physician-supervised programs like GOAL.MD offer access to compounded GLP-1s as part of a comprehensive medical [weight loss](/weight-loss) plan. These programs include physician consultations, medication, and ongoing support, providing a structured and monitored approach to using these medications.

Exploring Alternative Covered Medications

If continuing your current GLP-1 is not financially feasible, schedule a consultation with your physician to discuss alternative treatments that are on your Medicare plan's formulary. There may be other effective options available for managing your condition.

For type 2 diabetes, this could include other GLP-1 agonists that have better coverage under your plan, or drugs from different classes like SGLT2 inhibitors (e.g., Jardiance, Farxiga), DPP-4 inhibitors (e.g., Januvia), or the long-standing first-line therapy, metformin.

For weight management, options under Medicare are more limited. However, some Medicare Advantage (Part C) plans may offer supplemental benefits for wellness programs or even certain anti-obesity medications not typically covered by Part D. It is essential to review your plan's Evidence of Coverage document.

A thorough discussion with your healthcare provider is the best way to navigate this. They can help you weigh the clinical pros and cons of switching therapies and find a new treatment plan that is both medically sound and financially sustainable for you.

Bottom Line

Losing Medicare coverage for a GLP-1 medication can be challenging, but several options exist to maintain your continuity of care. The first step is to understand why coverage was terminated and to work with your doctor to file a formal appeal with strong medical justification.

While awaiting an appeal decision, investigate manufacturer Patient Assistance Programs, but be aware that Medicare beneficiaries are often excluded. Also, research the cash-price discounts available through pharmacy savings cards.

Discuss all clinically appropriate alternative medications with your physician that are covered by your Medicare plan. For some, physician-supervised programs that use compounded medications from licensed U.S. pharmacies may be a practical pathway, especially during official drug shortages.

This information is for educational purposes only and does not constitute medical advice. Please consult with a healthcare professional for personalized guidance.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.